News coverage about TRACON Pharmaceuticals (NASDAQ:TCON) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.4430412167287 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
TRACON Pharmaceuticals (NASDAQ:TCON) traded up 2.33% on Friday, reaching $2.20. 197,960 shares of the company’s stock were exchanged. The company’s market cap is $36.64 million. The stock’s 50 day moving average is $2.23 and its 200 day moving average is $3.21. TRACON Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $7.30.
TRACON Pharmaceuticals (NASDAQ:TCON) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.12. TRACON Pharmaceuticals had a negative return on equity of 119.93% and a negative net margin of 963.11%. The company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.81 million. On average, equities analysts anticipate that TRACON Pharmaceuticals will post ($1.57) earnings per share for the current year.
TCON has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Stifel Nicolaus lowered their price target on shares of TRACON Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, June 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. TRACON Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $8.38.
TRADEMARK VIOLATION NOTICE: “TRACON Pharmaceuticals (NASDAQ:TCON) Receives Daily Media Sentiment Rating of 0.09” was originally reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/tracon-pharmaceuticals-nasdaqtcon-receiving-somewhat-favorable-press-coverage-report-shows-updated.html.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.